Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol

Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.